Caroline Corner


Before the Bell: Cantor Reiterates Buy on Aerie Pharmaceuticals Inc Following Clinical Update

In a research report released Friday, Cantor analyst Caroline Corner reiterated a Buy rating on shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) with a price …

Cantor Heads to Sidelines on Organovo Holdings Inc; Slashes Price Target

In a research report released today, Cantor analyst Caroline Corner downgraded shares of Organovo Holdings Inc (NYSE:ONVO) to Hold rating and reduced the price target to …

Cantor Fitzgerald Remains Optimistic on StemCells Inc (STEM) Ahead of Anticipated GA Data

Cantor Fitzgerald analyst Caroline Corner weighed in with her opinions on StemCells Inc (NASDAQ:STEM) ahead of Geographic Atrophy data that is supposed to be …

Here’s Why Cantor Raised Price Target for Organovo Holdings Inc (ONVO) by 20%

In a research report issued today, Cantor analyst Caroline Corner maintained a Buy rating on Organovo Holdings Inc (NYSE:ONVO) and raised the price …

Cantor Initiates Buy On StemCells Inc; Sees 200% Upside For The Stock

In a research report issued Friday, Cantor Fitzgerald analyst Caroline Corner initiated coverage on shares of StemCells Inc (NASDAQ:STEM) with a Buy rating and price …

Cantor Heads to Sidelines on Aerie Pharmaceuticals Inc Due to Disappointing Phase 3 Trial for Rhopressa

In a research report published Friday, Cantor analyst Caroline Corner downgraded shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI), and significantly reduced the price target to $12.00 (from $40), …

Cantor Initiates Buy on Organovo Holdings Inc; Sees 15% Upside For The Stock

In a research report published Wednesday, Cantor Fitzgerald analyst Caroline Corner initiated coverage on shares of Organovo Holdings Inc (NYSE:ONVO) with a Buy rating and …

Cantor Sees 72% Upside For Alimera Shares As Commercial Rollout Going Well

Cantor analyst Caroline Corner initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) with a Buy rating and a $10 price target, which represents a potential upside of 72% …

Cantor Maintains Buy On Cerus As Flurry Of News Are Expected

In a research report published this morning, Cantor analyst Caroline Corner maintained a Buy rating on Cerus (NASDAQ:CERS) with a $6.00 price target, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts